EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is miR-21 A Therapeutic Target in Cardiovascular Disease?

Antoinette Holland, Molly Enrick, Arianna Diaz, Liya Yin

International Journal of Drug Discovery and Pharmacology · 2023

DOI: 10.53941/ijddp.0201003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Discovery and Pharmacology, 2023. Verfasst von Antoinette Holland und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Medical Sciences, Northeast Ohio Medical University, Ohio 44272, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

microRNA-21 (miR-21) serves a multitude of functions at the molecular level through its regulation of messenger RNA. Previous research has sparked interest in the role of miR-21 as a potential therapeutic target in cardiovascular diseases. miR-21 expression contributes to the differentiation, proliferation, and maturation of many cell types, such as fibroblasts, endothelial cells, cardiomyocytes, and endothelial progenitor cells. The function of miR-21 depends upon its expression level in the specific cell types and downstream targets, which determine cell fate. Under pathological conditions, the expression level of miR-21 is altered, leading to abnormal gene regulation of downstream signaling and cardiovascular diseases such as hypertension, cardiac hypertrophy and fibrosis, atherosclerosis, and heart failure. Agomirs or antagomirs can be introduced into the respective tissue type to reverse or stop the progression of the disease. Exosomes in the extracellular vesicles, which mediate many cellular events with high biocompatibility, have a high potential of efficiently delivering miR-21 to their targeted cells. The critical role of miR-21 in cardiovascular disease (CVD) is indisputable, but there are controversial reports on the function of miR-21 in the same disease. This discrepancy sparks interest in better understanding the role of miR-21 in different tissues under different stages of various diseases and the mechanism of how miR-21 inhibitors work.

Schlagwörter

Stichwörter der Autor:innen

atherosclerosisexosomesheart failuremiR inhibitormiR mimicmiR-21microRNAmyocardial infarction

Autor:innen und Institutionen

  • Department of Integrative Medical Sciences, Northeast Ohio Medical University, Ohio 44272, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Holland, A., Enrick, M., Diaz, A., & Yin, L. (2023). Is miR-21 A Therapeutic Target in Cardiovascular Disease?. International Journal of Drug Discovery and Pharmacology. https://doi.org/10.53941/ijddp.0201003

Vancouver

Holland A, Enrick M, Diaz A, Yin L. Is miR-21 A Therapeutic Target in Cardiovascular Disease?. International Journal of Drug Discovery and Pharmacology. 2023. doi:10.53941/ijddp.0201003

BibTeX
@article{Holland2023,
  author = {Holland, Antoinette and Enrick, Molly and Diaz, Arianna and Yin, Liya},
  title = {Is miR-21 A Therapeutic Target in Cardiovascular Disease?},
  journal = {International Journal of Drug Discovery and Pharmacology},
  year = {2023},
  doi = {10.53941/ijddp.0201003}
}
Kostenlos starten →